Clinical Trial Update: Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06) [Phase 1, Phase 2]

View source ↗

Summary

This document describes Substudy 06D of a Phase 1/2 clinical trial evaluating pembrolizumab in combination therapies for second-line gastroesophageal adenocarci…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer
• Gastric Cancer
• Gastroesophageal Junction Cancer

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Gastroesophageal Junction, Gastroesophageal Adenocarcinoma | Phase 1, Phase 2 | Status: RECRUITING